Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

French Industry Welcomes Moves To Speed Up Access To Innovative Drugs

Executive Summary

A French government/industry discussion forum has come up with concrete plans for accelerating access to innovative medicines by streamlining clinical trial approval and price negotiations.

You may also be interested in...



Over-Regulation Is Damaging French Pharma Sector

Leem says “Inconsistent and unpredictable” policies are hitting industry’s competitiveness and limiting patients’ access to new medicines.

French Gene & Cell Therapy Trials To Get Own Fast-Track Approval Process

Experimental gene and cell therapy products are to get a boost from the French regulator in the form of a new fast-track clinical trial approval process. This is the third accelerated pathway to be introduced as part of efforts to speed up patient access to new medicines.

French 2019 Budget A Mix Of Good And Bad News For Pharma

The French government is proposing to extend the use of the temporary use authorization system for unapproved drugs and to increase the rate of generic prescribing. It has also set a low threshold for the increase in pharmaceutical sales that triggers the payback mechanism.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS123480

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel